Promisemed Hangzhou Meditech Co (BJSE:920069) Notes Receivable: ¥0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BJSE:920069 Promisemed Hangzhou Meditech Co Ltd BJSE:920069
18 GF Score
Price ¥33.28
! 1 Warning Sign
View Full Analysis

What is Promisemed Hangzhou Meditech Co Notes Receivable?

Promisemed Hangzhou Meditech Co BJSE:920069 18 Notes Receivable is ¥0.0 Mil as of Jun. 2026. GuruFocus rates BJSE:920069 with a GF Score™ of 18/100. The stock has 1 warning sign investors should review.

Promisemed Hangzhou Meditech Co's Notes Receivable for the quarter that ended in Jun. 2026 was ¥0.0 Mil.

Promisemed Hangzhou Meditech Co Notes Receivable Related Terms

Promisemed Hangzhou Meditech Co Notes Receivable Historical Data

* Premium members only.

The historical data trend for Promisemed Hangzhou Meditech Co's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Promisemed Hangzhou Meditech Co Notes Receivable Chart

Promisemed Hangzhou Meditech Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Notes Receivable
0.00 0.00 0.00 0.00

Promisemed Hangzhou Meditech Co Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BJSE:920069
18GF Score
Promisemed Hangzhou Meditech Co Ltd BJSE:920069
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Promisemed Hangzhou Meditech Co Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ¥0.0 Mil mean?
Promisemed Hangzhou Meditech Co (BJSE:920069) has a Notes Receivable of ¥0.0 Mil as of Jun. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Promisemed Hangzhou Meditech Co and its competitors.
Is Promisemed Hangzhou Meditech Co's Notes Receivable too high?
Promisemed Hangzhou Meditech Co's current Notes Receivable is ¥0.0 Mil. Overall, Promisemed Hangzhou Meditech Co has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Promisemed Hangzhou Meditech Co's Notes Receivable compare to ISRG and BDX?
Promisemed Hangzhou Meditech Co's Notes Receivable of ¥0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Devices & Instruments company?
A good Notes Receivable depends on the Medical Devices & Instruments industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Promisemed Hangzhou Meditech Co and its competitors. Promisemed Hangzhou Meditech Co's current Notes Receivable is ¥0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Promisemed Hangzhou Meditech Co stock overvalued right now?
Promisemed Hangzhou Meditech Co (BJSE:920069) has a current Notes Receivable of ¥0.0 Mil. The current Notes Receivable is ¥0.0 Mil. Promisemed Hangzhou Meditech Co's overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Promisemed Hangzhou Meditech Co (BJSE:920069), the current Notes Receivable is ¥0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Promisemed Hangzhou Meditech Co Business Description

Address No. 1388 Cangxing Street, Building 1, Cangqian Subdistrict, Yuhang District, Zhejiang Province, Hangzhou, CHN, 311121
Promisemed Hangzhou Meditech Co Ltd is engaged in the Research, development, production and sales of diabetes care, universal drug delivery and infusion, and minimally invasive interventional medical devices.
18GF Score

Get the complete analysis for BJSE:920069

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥33.28
Price